[{"id":"fe4a2bc5-bd15-47c3-afe5-cf03631d12c9","acronym":"KEYNOTE-045","url":"https://clinicaltrials.gov/study/NCT02256436","created_at":"2021-01-17T17:31:22.874Z","updated_at":"2024-07-02T16:36:24.237Z","phase":"Phase 3","brief_title":"A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)","source_id_and_acronym":"NCT02256436 - KEYNOTE-045","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • paclitaxel • docetaxel • Javlor (vinflunine)"],"overall_status":"Completed","enrollment":" Enrollment 542","initiation":"Initiation: 10/22/2014","start_date":" 10/22/2014","primary_txt":" Primary completion: 09/07/2016","primary_completion_date":" 09/07/2016","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2021-09-20"},{"id":"e6912c33-43ae-452f-be31-c1d1612bbe66","acronym":"","url":"https://clinicaltrials.gov/study/NCT01953003","created_at":"2021-01-18T08:51:26.187Z","updated_at":"2024-07-02T16:36:59.947Z","phase":"Phase 3","brief_title":"Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT01953003","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Javlor (vinflunine)"],"overall_status":"Completed","enrollment":" Enrollment 112","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 07/01/2017","primary_completion_date":" 07/01/2017","study_txt":" Completion: 07/01/2017","study_completion_date":" 07/01/2017","last_update_posted":"2019-05-02"},{"id":"44ca8fb9-ea66-476d-8ee0-f430111b3a07","acronym":"","url":"https://clinicaltrials.gov/study/NCT00450515","created_at":"2021-01-18T01:35:41.636Z","updated_at":"2024-07-02T16:37:27.243Z","phase":"Phase 2","brief_title":"Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer","source_id_and_acronym":"NCT00450515","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Javlor (vinflunine)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2007","start_date":" 03/01/2007","primary_txt":" Primary completion: 01/01/2009","primary_completion_date":" 01/01/2009","study_txt":" Completion: 01/01/2009","study_completion_date":" 01/01/2009","last_update_posted":"2016-12-06"}]